10 February 2016

Manganese takes black cab to Azerbaijan

03/03/11 Ben Jaglom

Manganese Bronze (MNG), the manufacturer of the London Taxi has announced that it has won a substantial order from the Republic of Azerbaijan.

The company, which last year moved to AIM after 70 years on the main market, reported that it would be supplying 1,000 taxis in a deal worth $27 million through its joint venture with Chinese car manufacturer Geely with a new private company 'the Baku Taxi Company' having been created to update the capital's fleet with London taxis.

Speaking to Growth Company Investor, CEO John Russell explained that the 'oil-rich country' had been talking to Manganese 'for a year' adding that the country had decided it wanted to upgrade its taxis and that Manganese represented the 'best prospect' for new taxis.

Conceding that it is 'an unusual place' Russell notes that it does have 'a direct flight from Heathrow to Baku.' Russell argued that London's taxis are known for having 'the best service' of anywhere in the world which he opined was 'half because of the taxi and half because of the customer service.'

As part of the goal of maintaining the reputation of the London taxi, he remarked that Manganese would be undertaking training in Baku on getting local drivers 'up to speed' that would include the development of 'customer handling skills' and the usage of the taxi, with Russell enthusing that Manganese can make versions 'for almost any conditions in the world.'

Looking forward he drew attention to recent sales to territories including Saudi Arabia and Bahrain, ading that the company is having 'a number of similar chats along the same lines.'

Recommended by Growth Company Investor in July at 41p, the shares, which have gained almost 50 percent this morning are currently trading at 55.25p having started the day at 37p. We reiterate our speculative buy advice.

Tags: An unusual place, Azerbaijan, Baku, Black cab, Direct flight to Heathrow, Guv'nor, Manganese Bronze

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Diurnal to profit from orphan drugs 09/02/16

Drug developer Diurnal (AIM: DNL) joined AIM a couple of days before Christmas. It already has one product in final phase III clinical trials and another due to start them shortly. So revenue generation at Diurnal should be a lot closer than at many junior biotechs. If all goes according to plan lead product Infacort should hit the market in 2018.

Forbidden focuses on selling 05/02/16

Forbidden Technologies (AIM: FBT) has been around a long time but has failed to generate much in the way of revenues, despite having a product that sounds like it should be a winner. There were board changes last year and new CEO Aziz Musa is shifting resources towards selling and away from technological development. This has to be the right strategy and we should find out if it’s working as this year unfolds.

Wash those nits right out of your hair! 04/02/16

Tyratech (AIM: TYRU) offers a compelling product proposition. Controlling bugs and parasites using conventional pesticides is both harmful to the environment and ineffective. Over the years insects have built up resistance to many of the chemicals used to kill them. So Tyratech’s natural products are not only safer but also a lot more effective than the competition. 

Angling for a cancer breakthrough 01/02/16

Results from medical device manufacturer Angle (AIM: AGL) showed its innovative Parsortix system to be nicely on track. The first commercial sales for research use have just been made and three leading cancer centres are moving forward with trials that will support its clinical use in the diagnosis of ovarian cancer.

2016 Quoted Company Award Winners announced 29/01/16

The 12th annual Grant Thornton Quoted Company Awards took place this week at the Natural History Museum in London. This prestigious event is organised by Growth Company Investor and is a celebration of the success and achievements of the UK’s smaller company sector. We published the shortlisted nominees for each award category earlier in January; so read on to see who the winners were...

Plexus hammered by oil industry shutdown 25/01/16

In the middle of 2014 Plexus (AIM: POS) was riding high with a share price of 320p giving the company a market value of £270 million. Today’s profit warning has seen the shares slump 40 per cent to just 73p, valuing Plexus at a mere £65 million. As an engineering company selling mainly into the oil industry, we shouldn’t be too surprised by downgrades. But the severity is startling.

More News